Results 31 to 40 of about 126,024 (329)

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

JAMA Oncology, 2020
Key Points Question Does adding ipilimumab to nivolumab improve clinical outcomes for patients with advanced hepatocellular carcinoma previously treated with sorafenib?
T. Yau, Yoon-Koo Kang, Tae-You Kim, A. El-Khoueiry, A. Santoro, B. Sangro, I. Melero, M. Kudo, M. Hou, A. Matilla, F. Tovoli, J. Knox, A. Ruth He, B. El-Rayes, M. Acosta-Rivera, Ho Yeong Lim, J. Neely, Yun Shen, T. Wisniewski, Jeffrey Anderson, Chiun Hsu   +20 more
semanticscholar   +1 more source

Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3). [PDF]

PLoS ONE, 2014
Hand-foot skin reaction is a most common multi-kinase inhibitor-related adverse event. This study aimed to examine whether the toxicity of sorafenib and sunitinib for human keratinocytes was associated with inhibiting signal transduction and activator of
Kazuhiro Yamamoto, Atsushi Mizumoto, Kohji Nishimura, Atsushi Uda, Akira Mukai, Kazuhiko Yamashita, Manabu Kume, Hiroo Makimoto, Toshinori Bito, Chikako Nishigori, Tsutomu Nakagawa, Takeshi Hirano, Midori Hirai   +12 more
doaj   +1 more source

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Journal of Clinical Oncology, 2021
PURPOSE Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies.
S. Qin, F. Bi, S. Gu, Y. Bai, Zhendong Chen, Zishu Wang, J. Ying, Yinying Lu, Z. Meng, H. Pan, Ping Yang, He-long Zhang, Xi Chen, A. Xu, C. Cui, B. Zhu, Jian Wu, Xiao-ming Xin, Jufeng Wang, Jin-lu Shan, Junhui Chen, Zhendong Zheng, Li Xu, X. Wen, Z. You, Z. Ren, Xiufeng Liu, M. Qiu, Liqing Wu, F. Chen   +29 more
semanticscholar   +1 more source

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

BMC Cancer, 2017
Background Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear.
Fei-Xiang Wu, Jie Chen, Tao Bai, Shao-Liang Zhu, Tian-Bo Yang, Lu-Nan Qi, Ling Zou, Zi-Hui Li, Jia-Zhou Ye, Le-Qun Li   +9 more
doaj   +1 more source

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis

Frontiers in Pharmacology, 2022
Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib ...
Zhi-Yong Liu, Zhi-Yong Liu, Dan-Ying Zhang, Dan-Ying Zhang, Xia-Hui Lin, Xia-Hui Lin, Jia-Lei Sun, Jia-Lei Sun, Weinire Abuduwaili, Weinire Abuduwaili, Guang-Cong Zhang, Guang-Cong Zhang, Ru-Chen Xu, Ru-Chen Xu, Fu Wang, Fu Wang, Xiang-Nan Yu, Xiang-Nan Yu, Xuan Shi, Xuan Shi, Bin Deng, Ling Dong, Ling Dong, Shu-Qiang Weng, Shu-Qiang Weng, Ji-Min Zhu, Ji-Min Zhu, Xi-Zhong Shen, Xi-Zhong Shen, Xi-Zhong Shen, Tao-Tao Liu, Tao-Tao Liu   +31 more
doaj   +1 more source

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).

Journal of Clinical Oncology, 2020
PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene (FLT3-ITD) have a poor prognosis, frequently ...
A. Burchert, G. Bug, Lea Fritz, J. Finke, M. Stelljes, C. Röllig, E. Wollmer, R. Wäsch, M. Bornhäuser, T. Berg, F. Lang, G. Ehninger, H. Serve, R. Zeiser, E. Wagner, N. Kröger, C. Wolschke, M. Schleuning, K. Götze, C. Schmid, M. Crysandt, Eva Esseling, D. Wolf, Ying Wang, A. Böhm, C. Thiede, T. Haferlach, Christian Michel, W. Bethge, T. Wündisch, C. Brandts, Susanne Harnisch, M. Wittenberg, H. Hoeffkes, Susanne Rospleszcz, A. Burchardt, A. Neubauer, Markus Brugger, K. Strauch, C. Schade-Brittinger, S. Metzelder   +40 more
semanticscholar   +1 more source

BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. [PDF]

PLoS ONE, 2013
The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC).
Wei-Chien Huang, Yi-Ling Hsieh, Chao-Ming Hung, Pei-Hsuan Chien, Yu-Fong Chien, Lei-Chin Chen, Chih-Yen Tu, Chia-Hung Chen, Sheng-Chieh Hsu, Yueh-Ming Lin, Yun-Ju Chen   +10 more
doaj   +1 more source

Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with Sorafenib with or without Erlotinib in the SEARCH Trial [PDF]

, 2016
Purpose: Sorafenib is the current standard therapy for advanced HCC, but validated biomarkers predicting clinical outcomes are lacking. This study aimed to identify biomarkers predicting prognosis and/or response to sorafenib, with or without erlotinib,
Evans, T.R. Jeffrey, Gane, Edward, Jeffers, Michael, Kang, Yoon-Koo, Meinhardt, Gerold, Peña, Carol E.A., Rosmorduc, Olivier, Ross, Paul, Santoro, Armando, Vogel, Arndt, Zhu, Andrew X.   +10 more
core   +1 more source

Artesunate Sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy

Autophagy, 2023
Sorafenib is the most widely used first-line drug for the treatment of the advanced hepatocellular carcinoma (HCC). Unfortunately, sorafenib resistance often limits its therapeutic efficacy.
Zhaochen Ma, Wenjia Chen, Yudong Liu, Lingxiang Yu, Xia Mao, Xiaodong Guo, F. Jiang, Q. Guo, Na Lin, Yanqiong Zhang   +9 more
semanticscholar   +1 more source

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source